Share Twitter LinkedIn Facebook Email Christopher Crane, MD of Memorial Sloan-Kettering gives an overview of his presentation, What is the Optimal Neoadjuvant Strategy in Pancreatic Cancer, which was debated at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia Acute Lymphoblastic Leukemia 3 Mins Read
FDA Approves Inotuzumab Ozogamicin (BESPONSA) for Acute Lymphoblastic Leukemia in Pediatric Patients [Exclusive Video] Acute Lymphoblastic Leukemia 3 Mins Read
Spotlight on CAR T-cell Therapy in 2024: Advances & Clinical Insights Acute Lymphoblastic Leukemia 3 Mins Read